Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: A randomized trial

Annals of Internal Medicine

Volumn 153, Issue 6, 2010, Pages 358-367

  Vadhan Raj, Saroj ^a   Trent, Jonathan ^a   Patel, Shreyaskumar ^a   Zhou, Xiao ^a   Johnson, Marcella M ^a   Araujo, Dejka ^a   Ludwig, Joseph A ^a   O'Roark, Shana ^a   Gillenwater, Ann M ^a   Bueso Ramos, Carlos ^a   El Naggar, Adel K ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; PALIFERMIN; PLACEBO; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; KERATINOCYTE GROWTH FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLUSHING; FOLLOW UP; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SARCOMA; SELF REPORT; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; STRUCTURED QUESTIONNAIRE; TASTE; WORLD HEALTH ORGANIZATION; DRUG EFFECT; MIDDLE AGED; MOUTH MUCOSA; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; DOXORUBICIN; FEMALE; FIBROBLAST GROWTH FACTOR 7; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; SARCOMA; STOMATITIS; YOUNG ADULT;

EID: 77957343771     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-153-6-201009210-00003     Document Type: Article

References (29)

1. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004;100:1995-2025. [PMID: 15108222]
2. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck. 2003;25:1057-70. [PMID: 14648865] (Pubitemid 37475269)
3. Mead GM. Management of oral mucositis associated with cancer chemotherapy. Lancet. 2002;359:815-6. [PMID: 11897276]
4. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. Cancer. 2008;112:1600-6. [PMID: 18300265] (Pubitemid 351441174)
5. Potting CM, Uitterhoeve R, Op Reimer WS, Van Achterberg T. The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review. Eur J Cancer Care (Engl). 2006;15:431-9. [PMID: 17177899] (Pubitemid 44893370)
6. Epstein JB, Klasser GD. Emerging approaches for prophylaxis and management of oropharyngeal mucositis in cancer therapy. Expert Opin Emerg Drugs. 2006;11:353-73. [PMID: 16634706]
7. Lalla RV, Peterson DE. Treatment of mucositis, including new medications. Cancer J. 2006;12:348-54. [PMID: 17034671]
8. Worthington HV, Clarkson JE, Eden OB. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev. 2007:CD000978. [PMID: 17943748]
9. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber- Durlacher JE, et al; Mucositis Study Section of the Multinational Association of Supportive Care in Cancer and the International Society for Oral Oncology. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820-31. [PMID: 17236223]
10. Papas AS, Clark RE, Martuscelli G, O'Loughlin KT, Johansen E, Miller KB. A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:705-12. [PMID: 12692611]
11. Rubin JS, Osada H, Finch PW, Taylor WG, Rudikoff S, Aaronson SA. Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A. 1989;86:802-6. [PMID: 2915979]
12. Farrell CL, Rex KL, Kaufman SA, Dipalma CR, Chen JN, Scully S, et al. Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol. 1999;75:609-20. [PMID: 10374943]
13. Farrell CL, Bready JV, Rex KL, Chen JN, DiPalma CR, Whitcomb KL, et al. Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res. 1998;58:933-9. [PMID: 9500453]
14. Borges L, Rex KL, Chen JN, Wei P, Kaufman S, Scully S, et al. A protective role for keratinocyte growth factor in a murine model of chemotherapy and radiotherapy-induced mucositis. Int J Radiat Oncol Biol Phys. 2006;66:254-62. [PMID: 16904525] (Pubitemid 44175675)
15. Dörr W, Heider K, Spekl K. Reduction of oral mucositis by palifermin (rHuKGF): dose-effect of rHuKGF. Int J Radiat Biol. 2005;81:557-65. [PMID: 16298937] (Pubitemid 41784877)
16. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351:2590-8. [PMID: 15602019]
17. Stiff PJ, Emmanouilides C, Bensinger WI, Gentile T, Blazar B, Shea TC, et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol. 2006;24:5186-93. [PMID: 16391299] (Pubitemid 46646481)
18. Stiff PJ, Erder H, Bensinger WI, Emmanouilides C, Gentile T, Isitt J, et al. Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006;37:393-401. [PMID: 16415901] (Pubitemid 43250474)
19. Meropol NJ, Somer RA, Gutheil J, Pelley RJ, Modiano MR, Rowinsky EK, et al. Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol. 2003;21:1452-8. [PMID: 12697866] (Pubitemid 46594095)
20. Rosen LS, Abdi E, Davis ID, Gutheil J, Schnell FM, Zalcberg J, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006;24:5194-200. [PMID: 17075109] (Pubitemid 46631362)
21. Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol. 1992;10:1266-77. [PMID: 1634916]
22. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, et al.; MRC BO06 and EORTC 80931 collaborators. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112-28. [PMID: 17227995]
23. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317-21. [PMID: 9626808]
24. Bartek J, Lukas J. Cell cycle. Order from destruction. Science. 2001;294:66-7. [PMID: 11588240]
25. Neganova I, Lako M. G1 to S phase cell cycle transition in somatic and embryonic stem cells. J Anat. 2008;213:30-44. [PMID: 18638068]
26. Lee JJ, Hess KR, Dubin JA. Extensions and applications of event charts. Am Stat. 2000;54:63-70.
27. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-54.
28. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496-509.
29. Gray RJ. cmprsk: subdistribution analysis of competing risks. R package version 2.1-5. 2004. Accessed at http://biowww.dfci.harvard.edu/~gray on 26 July 2010.